

RESEARCH

Open Access



The effect of the volemic and cardiac status on brain oxygenation in patients with subarachnoid hemorrhage: a bi-center cohort study

Verena Rass^{1*} , Elisa Gouvea Bogossian², Bogdan-Andrei Ianosi^{1,3}, Lorenzo Peluso², Mario Kofler¹, Anna Lindner¹, Alois J. Schiefecker¹, Lauma Putnina¹, Max Gaasch¹, Werner O. Hackl³, Ronny Beer¹, Bettina Pfausler¹, Fabio Silvio Taccone² and Raimund Helbok¹

Abstract

Background: Fluid management in patients after subarachnoid hemorrhage (SAH) aims at the optimization of cerebral blood flow and brain oxygenation. In this study, we investigated the effects of hemodynamic management on brain oxygenation by integrating advanced hemodynamic and invasive neuromonitoring.

Methods: This observational cohort bi-center study included data of consecutive poor-grade SAH patients who underwent pulse contour cardiac output (PiCCO) monitoring and invasive neuromonitoring. Fluid management was guided by the transpulmonary thermodilution system and aimed at euvolemia (cardiac index, CI \geq 3.0 L/min/m²; global end-diastolic index, GEDI 680–800 mL/m²; stroke volume variation, SVV < 10%). Patients were managed using a brain tissue oxygenation (P_{bt}O₂) targeted protocol to prevent brain tissue hypoxia (BTH, P_{bt}O₂ < 20 mmHg). To assess the association between CI and P_{bt}O₂ and the effect of fluid challenges on CI and P_{bt}O₂, we used generalized estimating equations to account for repeated measurements.

Results: Among a total of 60 included patients (median age 56 [IQRs 47–65] years), BTH occurred in 23% of the monitoring time during the first 10 days since admission. Overall, mean CI was within normal ranges (ranging from 3.1 \pm 1.3 on day 0 to 4.1 \pm 1.1 L/min/m² on day 4). Higher CI levels were associated with higher P_{bt}O₂ levels (Wald = 14.2; p < 0.001). Neither daily fluid input nor fluid balance was associated with absolute P_{bt}O₂ levels (p = 0.94 and p = 0.85, respectively) or the occurrence of BTH (p = 0.68 and p = 0.71, respectively). P_{bt}O₂ levels were not significantly different in preload dependent patients compared to episodes of euvolemia. P_{bt}O₂ increased as a response to fluid boluses only if BTH was present at baseline (from 13 \pm 6 to 16 \pm 11 mmHg, OR = 13.3 [95% CI 2.6–67.4], p = 0.002), but not when all boluses were considered (p = 0.154).

Conclusions: In this study a moderate association between increased cardiac output and brain oxygenation was observed. Fluid challenges may improve P_{bt}O₂ only in the presence of baseline BTH. Individualized hemodynamic management requires advanced cardiac and brain monitoring in critically ill SAH patients.

*Correspondence: verena.rass@tirol-kliniken.at; verena@rass.info
¹ Neurological Intensive Care Unit, Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
Full list of author information is available at the end of the article

Keywords: Subarachnoid hemorrhage, Fluid management, PiCCO, Critical care, Multimodal neuromonitoring, Brain oxygenation

Introduction

Optimal fluid management is crucial after subarachnoid hemorrhage (SAH) to maintain adequate cerebral blood flow (CBF), particularly in the setting of impaired autoregulatory capacity, and aims at the prevention of secondary brain injuries [1]. Evidence suggests that hypoperfusion and hypotension are associated with an increased risk of brain damage, requiring prompt fluid resuscitation, especially in the early period after the initial bleeding [2]. In contrast, fluid overload can lead to complications, such as pulmonary or cerebral edema, and has been associated with poor functional outcome [3, 4]; as such, international guidelines advocate the achievement of “euvoemia” in SAH patients [1].

However, monitoring of the fluid status and intravascular volume can be challenging in this setting. Traditional methods, such as the assessment of fluid balance and/or monitoring of vital signs [1], the use of echocardiography [5], or passive leg raising maneuvers [6], may not be sufficient in poor-grade SAH patients with hemodynamic impairment, including myocardial stunning [7]. The semi-invasive transpulmonary thermodilution system has been developed to achieve a goal-directed hemodynamic support and optimal fluid management. It allows for accurate prediction of fluid responsiveness at the bedside, by measuring the cardiac output and the volume status simultaneously [8]. Several studies showed its feasibility in SAH patients, and a goal-directed therapy based on this hemodynamic monitoring may potentially decrease the occurrence of delayed cerebral ischemia (DCI) and improve the management of hemodynamically unstable SAH patients [9–11].

Individualized therapy to specifically reduce secondary brain injuries may be accomplished by the use of invasive multimodal neuromonitoring in poor-grade SAH patients [12, 13]. Brain tissue oxygenation ($P_{bt}O_2$) is an important physiologic target and reflects the equilibrium between cerebral perfusion, oxygen delivery, oxygen consumption, and tissue diffusion into the brain parenchyma [14]. A pilot study, including 10 SAH patients, reported that fluid challenges resulted in an improved cardiac output and subsequently increased $P_{bt}O_2$ levels, particularly in those who were “fluid responders” [15]. Another study showed that hypervolemia, as part of the previously recommended hypertension, hypervolemia and hemodilution (triple-H) therapy, did not result into improved $P_{bt}O_2$ levels [16]. These studies underline that hemodynamic interventions should be individualized on brain

monitoring, such as brain oxygenation, to expect beneficial cerebral effects in SAH patients.

The aim of the current study was therefore to investigate the effect of fluid management and the cardiac function on brain oxygenation, by integrating advanced hemodynamic and invasive neuromonitoring tools. We hypothesized that a higher cardiac index (CI) would be associated with a better brain tissue oxygenation and that fluid challenges would result into a significant increase in brain tissue oxygenation.

Methods

Study design, setting, and participants

This study was designed according to the STROBE statement on observational cohort studies. We prospectively collected data of patients admitted to the ICU of two tertiary care centers (Medical University of Innsbruck, Austria; Erasme Hospital, Brussels, Belgium) between 2010 and 2019 diagnosed of non-traumatic subarachnoid hemorrhage. Inclusion criteria were as follows: (1) age ≥ 18 years; (2) neuromonitoring of intracranial pressure (ICP) and $P_{bt}O_2$ as part of clinical routine; and (3) concurrent advanced hemodynamic monitoring with a transpulmonary thermodilution system (Pulse Contour Cardiac Output, PiCCO; Pulsion Medical Systems SE, Munich, Germany). This study was approved by the local ethics committees (Medical University Innsbruck, AN3898 285/4.8, AM4091-292/4.6; Erasme Hospital Brussels, P2019/649). All patients in Innsbruck (IBK) gave informed consent according to local regulations and it was waived in Brussels (BRU). The conduct of this study conformed to the Declaration of Helsinki.

Clinical management and grading

Patients were clinically graded with use of the Hunt&Hess (H&H) grade on admission; poor grade was defined as scores of 4 or 5. The management conformed to international guidelines [17, 18], except for nimodipine which was administered intravenously in poor-grade patients in Innsbruck. Aneurysms were secured with means of neurosurgical clipping or endovascular coiling, after multi-disciplinary discussion in both centers. All patients were regularly followed for large-vessel vasospasm with daily transcranial color-coded duplex sonography (TCCS). Vasospasm was diagnosed in the setting of mean velocities > 120 cm/s in the anterior and/or middle cerebral artery or daily changes of > 50 cm/s. Delayed cerebral ischemia was defined as the occurrence of a new

focal neurologic deficit, a decrease of at least two points on the Glasgow Coma Scale, or a new infarct on the computed tomography (CT) or magnetic resonance imaging scan not attributable to other causes [19]. All patients were mechanically ventilated and received continuous drips of sufentanil, midazolam, propofol and/or ketamine, according to local practices.

Hemodynamic monitoring and fluid management

The use of advanced hemodynamic monitoring was based on (1) hemodynamic instability or (2) the presence of stunned myocardium on echocardiography. Continuous values of the CI and stroke volume variation (SVV) were recorded. Transpulmonary thermodilution was performed three times per day to calibrate for the assessment of cardiac volumes, extravascular lung water, using a 15 mL of cold ($<8^{\circ}\text{C}$) 0.9% saline bolus injected into the superior vena cava. Based on the thermodilution curves, estimations of the CI (normal range: 3.0–5.0 L/min/m²), global end-diastolic volume index (GEDI; 680–800 mL/m²), extravascular lung water index (ELWI; <7 mL/kg), and systemic vascular resistance index (SVRI; 1700–2400 dyn·s m²/cm⁵) were obtained [8]. SVV was only interpreted in the setting of a fully controlled ventilation mode (73% of the monitoring time). In the setting of low GEDI (<680 mL/m²) or high SVV ($>10\%$), patients were considered preload dependent.

Fluid management aimed at euvolemia and was directed by the PiCCO method by targeting normal CI, GEDI, SVV levels, and avoidance of fluid overload indicated by a high ELWI, signs of pulmonary edema on chest radiography, and blood gas analyses (i.e., low Horowitz index), and signs of peripheral edema in the absence of hypoalbuminemia and capillary leakage syndrome [20]. Euvolemia was maintained by volume replacement with isotonic crystalloids (IBK: Elomel Fresenius Kabi Austria, Graz, Austria, 302 mOsm/L 2014–2016 and Sodium-chloride 0.9%, 308 mOsm/L; Braun, Melsungen, Germany until 2014; BRU: Plasmalyte, Baxter Healthcare Ltd or Sodium-chloride 0.9%, 308 mOsm/L Baxter Healthcare Ltd) and fluid resuscitation was achieved with colloids or crystalloids (IBK: Gelofusin 274 mOsm/L; Braun, Melsungen, Germany; BRU: Plasmalyte, Baxter Healthcare Ltd). Diuretics (mainly furosemide) were used if necessary in the setting of fluid overload or decreased urine output. For hemodynamic augmentation, vasopressors (mainly noradrenaline) or fluids were used, as decided by the treating physician. Neurogenic stunned myocardium was diagnosed based on electrocardiographic and echocardiographic abnormalities associated with elevated troponin levels and the requirement for continuous inotropic drugs (i.e., milrinone or dobutamine) to improve impaired left ventricular function (if CI <3.0 L/min/m²)

[21]. In the presence of suspected hypocortisolism and high dependence on vasopressors, hydrocortisone (IBK: 8 mg/h as continuous drip, BRU: 50 mg q6h) was given.

Invasive multimodal neuromonitoring

The indications for invasive multimodal monitoring (ICP and P_{bt}O₂) were as follows: (1) poor-grade SAH; (2) anticipated prolonged mechanical ventilation; and (3) clinical or radiological signs suggestive of raised intracranial pressure. Neuromonitoring probes were placed into the hemisphere at greatest risk of secondary brain injury either through a frontal burr hole using a triple-lumen bolt or tunneled and placed in the white matter. Probe location was confirmed by brain CT scans obtained within 24 h from implantation. Brain oxygenation catheters (Licox[®] CCI.SB probes, Integra LifeSciences, Ratingen, Germany) and intraparenchymal ICP probes (Neurovent-P-temp, Raumedic[®], Helmbrechts, Germany) were used. Cerebral perfusion pressure was calculated by subtracting ICP from mean arterial pressure (MAP), measured at the level of the Monroe foramen (IBK) or at the level of the heart (BRU) which accounts for approximately 15 mmHg difference, with higher CPP levels when measured at the level of the heart. In clinical practice, brain tissue hypoxia (BTH) was treated if P_{bt}O₂ <20 mmHg lasted for >5 min according to local protocols (Additional file 1: Figs. S1, S2). Treatment options included increases of CPP ≥ 70 mmHg (Monroe level; IBK) or 90–100 mmHg (heart level; BRU) with vasopressors or fluid administration as indicated, targeting normocapnia (IBK: PaCO₂ >35 mmHg; BRU: PaCO₂ ≥ 40 mmHg; with consideration of ICP levels), optimization of oxygenation (IBK: PaO₂ ≥ 80 mmHg, BRU: PaO₂ 100–120 mmHg), RBC transfusions in anemic patients (IBK goal Hb ≥ 8 g/dL, BRU goal Hb ≥ 9 g/dL) and titration of analgesia, and sedation. For the current study, we used the definition of BTH when median hourly levels of P_{bt}O₂ were below 20 mmHg. Multimodal neuromonitoring was performed in the most vulnerable phase when patients were at risk of BTH and/or ICP crises in accordance with the manufacturer's recommendations.

Data collection

We prospectively collected demographics, hospital complications, and outcomes. Functional outcome was evaluated three months after the ictus with the use of the modified Rankin Scale Score (mRS), and poor functional outcome was defined as mRS >2 . Continuous variables, including PiCCO parameters (CI, SVV), neuromonitoring parameters (P_{bt}O₂, ICP, CPP), heart rate (HR), and MAP, were saved in a granularity of 3 min (IBK) or 15 min (BRU) using an electronic patient data management system (IBK: CentricityTM Critical Care 8.1 SP7;

GE Healthcare Information Technology, Dornstadt German; BRU: CareSuite 8.2.7.758 ICU; PICIS, N. Harris Computer Corporation Inc.) and calculated as hourly medians for the purposes of this study. In a subset of 18 patients (IBK) with available high-resolution data, we estimated the autoregulation state by using the Pressure reactivity index (PRx), calculated as a moving Pearson correlation between 30 consecutive 10-s averages of ICP and MAP, resulting in a moving 5-min time window, incremented in 10-s steps. [22].

Multimodal neuromonitoring parameters were checked for plausibly and artifacts were deleted manually. We discarded $P_{bt}O_2$ levels recorded within the initial stabilization time (at least 2 h of insertion). The following intermittent variables were derived from our patient data management systems, whenever available: daily sums of fluid input and balance, daily sums of vasopressor doses, the timing and volume of crystalloids and colloids, and PiCCO parameters (GEDI, ELWI, SVRI).

Study outcome measures

The primary study outcome measure was the effectiveness of fluid challenges on brain oxygenation. Fluid challenges were defined by the administration of 500–1000 mL colloid or crystalloid solution over 30–60 min. Further, we evaluated whether an association between the cardiac performance as assessed with CI and brain oxygenation exists.

Statistical analyses

We decided to analyze the first 10 days after bleeding to avoid a selection bias toward the most severe patients. Data availability was limited thereafter. The first day (first 24 h after admission) was denoted as day 0. We predefined time periods as follows: days 0–2 (representing the time of early brain injury), days 3–4, and days 5–9. Based on the observation that BTH most commonly occurred within the first 24 h, we performed separate analyses for days 1–9 to test whether the effects hold true after the initial stabilization time. The prevalence rates of BTH and CI ranges are given as percentage of the overall monitored time or as daily percentage, as indicated. Categorical variables are given as counts and percentage, continuous variables as median and interquartile range or mean and standard deviation. Based on variable distribution (tested by the Kolmogorov–Smirnov test and Shapiro–Wilk test), parametric and non-parametric procedures, including the *t*-test and Mann–Whitney *U* test, were used to assess differences between patients from the two centers. Categorical variables were analyzed using the Chi-squared and Fishers exact test. Univariate and/or multivariable generalized estimating equation (GEE) models were used for all analyses of repeated

measurements within one subject with an autoregressive process of the first order [23]. Covariates for multivariable models were preselected based on their clinical significance and specified accordingly. Changes of CI (ΔCI) and $P_{bt}O_2$ ($\Delta P_{bt}O_2$) were calculated as the difference between two consecutive hourly median values.

To study the effect of fluid challenges on CI and $P_{bt}O_2$, we also used GEE models with three time points: 1 h before administration (=baseline), during (one hour) administration, and 1 h after administration and used the median hourly values of selected variables. Separate analyses were done for CI responders (CI increase >10% from baseline) [15] vs. CI non-responders, for colloids vs. crystalloids and for the presence of BTH or normal brain tissue oxygenation at baseline. A *p*-value <0.05 was considered statistically significant. All analyses were performed with SPSS (IBM SPSS Statistics, Version 24.0 Armonk, NY, USA).

Results

Study population

Out of 167 (IBK: 81, BRU: 86) patients monitored with multimodal neuromonitoring, a total of 60 patients (IBK: 39, BRU: 21) met the inclusion criteria and were eventually included in the final analysis. Most patients were admitted with a poor H&H grade of 4–5 (62%) or deteriorated within 24 h (38%) of admission. The median age was 56 (47–65) years and 37 (62%) of patients were female; 73% of them had poor functional outcome at the 3-month follow-up. Detailed information on patients' demographics, hospital complications, and outcomes are given in Table 1; most characteristics were not significantly different across the two centers (Additional file 1: Table S1).

$P_{bt}O_2$ and CI over time

We analyzed a total of 353 days representing a median of 6 (4–8) days per patient. Brain tissue hypoxia occurred in 23% of the monitored time, with the highest prevalence observed on the first day of monitoring (44%; Fig. 1). Almost every patient (87%) developed one episode of BTH during the monitoring time, and the median time each patient spent with BTH was 20 (4–44) % over the study time. The prevalence of BTH (*p*=0.786) and absolute $P_{bt}O_2$ (*p*=0.611) were comparable across the study centers. Lower $P_{bt}O_2$ levels were associated with poor functional 3-month outcome after correction for age and admission H&H score (adjOR=0.99 [95% CI=0.98–0.99], *p*=0.011).

CI <3.0 L/min/m² was observed in 14%, CI between 3.0 and 5.0 L/min/m² in 75%, and CI >5.0 L/min/m² in 11% of the monitored time. This was reflected in mean daily CI levels being constantly within targeted levels ≥ 3.0 L/

Table 1 Baseline characteristics, complications, and outcomes

Clinical characteristics	N=60
Age in years	56 (47–65)
Female sex	37 (62)
Chronic heart failure	0 (0)
Previous myocardial infarction	3 (5)
Pre-existing hypertension	22 (37)
Smoking history	24 (40)
Admission H&H grade	1 3 (5) 2 6 (10) 3 14 (23) 4 6 (10) 5 31 (52)
GCS at ICU admission	3 (3–10)
LOC at ictus	36 (60)
Admission radiological characteristics	
Modified Fisher Scale	1 2 (3) 2 2 (3) 3 13 (22) 4 43 (72)
ICH present on admission CT scan	30 (50)
Hydrocephalus requiring EVD placement	42 (70)
Global cerebral edema	24 (40)
Aneurysm treatment	
Endovascular coiling	31 (52)
Neurosurgical clipping	27 (45)
Non-aneurysmal SAH ^a	2 (3)
Complications and treatment	
Neurogenic myocardial stunning	23 (38)
Pneumonia	42 (70)
Ventriculitis	7 (12)
Vasospasm	48 (80)
Delayed cerebral ischemia	25 (42)
Noradrenaline, daily dose in mg ^b	11 (5–25)
Dobutamine, daily dose in mg ^b	33 (0–258)
Phenylephrine, daily dose in mg ^b	0 (0–3)
Outcome characteristics	
Length of ICU stay in days	28 (18–39)
In-hospital mortality	14 (23)
3-month mRS	0 2 (3) 1 8 (13) 2 6 (10) 3 10 (17) 4 9 (15) 5 10 (17) 6 15 (25)

Data are given in median (IQR) and counts (%)

SAH subarachnoid hemorrhage, H&H Hunt and Hess, LOC loss of consciousness, ICH intracerebral hemorrhage, EVD external ventricular drain, mRS modified Rankin Scale

^a Aneurysm negative in repeated cerebral angiogram 2–3 weeks apart

Table 1 (continued)

^b Within the first 10 days

min/m², ranging from 3.1 ± 1.3 on day 0 to 4.1 ± 1.1 L/min/m² on day 4 (Fig. 2). Co-occurrence of CI values < 3.0 L/min/m² and BTH only occurred in a minority of episodes (3%) of the monitored time.



The association between CI and P_{bt}O₂ or BTH

Higher CI values were associated with higher P_{bt}O₂ levels (Wald = 14.2; *p* < 0.001) throughout the whole study time (days 0–2 *p* = 0.027; days 3–4 *p* = 0.018; days 5–9 *p* = 0.030; days 1–9 *p* < 0.001; Fig. 3). The association between CI and P_{bt}O₂ remained significant even after adjustment for the H&H grade, age, MAP, ICP, PaO₂, and interaction of CPP * CI (Wald = 6.8 *p* = 0.009; Additional file 1: Table S2). The same results were obtained in a sub-analysis of 18 patients with autoregulation recordings: higher CI values were linked to higher P_{bt}O₂ levels after adjustment for PRx (Wald = 10.9, *p* = 0.001).

Mean CI values were higher during normal brain tissue oxygenation measurements when compared to episodes of BTH (4.0 ± 1.0 vs. 3.8 ± 0.8 L/min/m²; *p* = 0.042). Accordingly, patients with higher CI levels had decreased odds of BTH (per 0.5 CI increase; OR = 0.88, [95% CI 0.78–0.995], *p* = 0.042). The association was particularly significant within days 3–4 (OR = 0.82, [95% CI 0.68–0.98], *p* = 0.026), but not within days 0–2 (*p* = 0.20) or days 5–9 (*p* = 0.21). A higher ΔCI was associated with a higher ΔP_{bt}O₂ (Wald = 10.5, *p* < 0.001; days 1–9: Wald = 9.7, *p* = 0.002). We found a significant effect of the interaction between the presence of BTH and CI (*p* < 0.001); however, the association between a higher ΔCI and a higher ΔP_{bt}O₂ held true when including the interaction in the model (Wald = 10.5, *p* = 0.001). Moreover, adjusting for PRx did not change the results in 18 patients (Wald = 8.8, *p* = 0.003). CI was abnormal (< 3.0 L/min/m²) in the presence of normal P_{bt}O₂ levels ≥ 20 mmHg in 10% of episodes.

Neurogenic stunned myocardium and P_{bt}O₂

Twenty-three (38%) patients developed neurogenic stunned myocardium after the bleeding and 21/23 (91%) were treated with inotropic drugs. In these patients, P_{bt}O₂ levels were higher as compared to those without stunned myocardium (29 ± 10 vs. 24 ± 11 mmHg, *p* = 0.005, Fig. 4) over the study period (days 1–9: 30 ± 10 vs. 24 ± 10 mmHg; *p* = 0.004). When adjusting the model for CI, MAP, ICP, PaO₂, H&H grade, and age, the results remained similar (*p* = 0.003). Accordingly, CI (*p* = 0.83) and MAP levels (*p* = 0.20) were similar across these groups. P_{bt}O₂ levels (per day, OR = 6.1 [95%






Fig. 3 A positive association between CI and $P_{bt}O_2$ levels was evident across all time phases. The line represents the local polynomial regression and the gray shades represent 95% CI

CI = 1.9–20.2], $p = 0.003$) and CI levels (per day, OR = 1.3 [95% CI = 1.1–1.5], $p = 0.003$) significantly increased from day 0 to day 1 in patients with stunned myocardium but not in those without ($P_{bt}O_2$: $p = 0.51$, CI: $p = 0.94$, respectively).

Volume status and $P_{bt}O_2$

Mean daily fluid input and fluid balance were 4.9 ± 1.9 L and 0.7 ± 1.7 L, respectively. Neither daily fluid input nor fluid balance was associated with absolute $P_{bt}O_2$ levels ($p = 0.94$, $p = 0.85$, respectively) or the occurrence of BTH ($p = 0.68$, $p = 0.71$, respectively). Low GEDI (<680 mL/m²) or high SVV (>10%) were observed in 31% and 25% of the monitored time, respectively; $P_{bt}O_2$ levels were similar in preload dependent patients as compared to episode of euvoemia (low GEDI: $p = 0.53$, high SVV: $p = 0.30$, respectively). A higher Δ CI was not associated with SVV > 10% ($p = 0.065$).

Fluid challenges and $P_{bt}O_2$

In total, 198 fluid boluses were analyzed in 48 patients, consisting of colloid (36%) or crystalloid fluid (64%) administration; 50 fluid boluses (25%) resulted in clinically significant CI increases (from 3.5 ± 1.2 to 4.4 ± 1.6 L/min/m², $p < 0.001$). A significant CI increase was more

frequently achieved with colloids than with crystalloids (38% vs. 18%, $p = 0.004$). $P_{bt}O_2$ did not change ($p = 0.89$) as a response to fluid boluses, both in fluid responders and non-responders ($p = 0.92$, $p = 1.00$, respectively; Fig. 5A, Additional file 1). An increase in $P_{bt}O_2$ was observed in the setting of BTH at baseline ($n = 49/198$, 25%; from 13 ± 6 to 16 ± 11 mmHg; OR = 13.3 [95% CI 2.6–67.4], $p = 0.002$; days 1–9: OR = 15.8 [95% CI 2.7–93.6], $p = 0.002$), even after adjusting for CI, MAP, ICP, PaO₂, age, and H&H grade (adjusted OR = 190.4 [95% CI 2.8–12,810.5], $p = 0.015$, Fig. 5B). Consequently, during these episodes in 26% normal $P_{bt}O_2$ levels were achieved after the fluid challenge. Changes of selected variables in response to the fluid administration are given in Table 2 and Additional file 1.

Discussion

In this study we report an association between the cardiac performance status, as assessed with CI, and brain oxygenation. Moreover, we could demonstrate an increase in $P_{bt}O_2$ after fluid challenges only in the setting of baseline brain tissue hypoxia.

We found a positive association between the cardiac performance reflected by a higher CI and higher brain tissue oxygen levels, which is in accordance with




Fig. 4 Patients with stunned myocardium had higher $P_{bt}O_2$ levels as compared to those without stunned myocardium ($p=0.005$). $P_{bt}O_2$ levels ($p=0.003$) rose from day 0 to day 1 in patients with stunned myocardium. The median administration of inotropic agents ranged from days 1 (1–3) to 5 (4–8) within the monitoring time

previous studies [15, 16]. Imaging studies, including positron emission tomography scans and xenon computed tomography, demonstrated that increases in cardiac output resulted in improved CBF [24, 25]. Accordingly, we found that increases in CI (ΔCI) were associated with increases in $P_{bt}O_2$ which is supported by a significant interaction between the presence of BTH and CI increase arguing against a spontaneous $P_{bt}O_2$ increase.

Patients with myocardial stunning had higher $P_{bt}O_2$ levels, which likely reflects a treatment effect with inotropic agents. This is further supported by the observation that $P_{bt}O_2$ increased in parallel to CI in the very early phase in patients with myocardial stunning but not in those without. The pathophysiology of myocardial stunning after SAH is multifactorial, including the activation of the hypothalamic–pituitary–adrenal (HPA) axis, catecholamine surge, and sympathetic and parasympathetic dysregulation [7]. Positive inotropic drugs, such as dobutamine, levosimendan, or milrinone, are used in the setting of severely impaired left ventricular function which can be monitored with the PiCCO (CI) [21]. Previous studies reported a drug-induced improvement of regional CBF (rCBF) in ischemic regions secondary to dobutamine administration in SAH patients underlining

its positive effect on the cerebrovascular besides the cardiac system. $P_{bt}O_2$ may reflect an important physiologic target variable to monitor treatment efficacy. In turn, the presence of BTH should elicit adequate treatment interventions to prevent brain tissue hypoxia. It is important to keep in mind that we followed a $P_{bt}O_2$ targeted treatment approach in these patients aiming at the prevention of BTH [26, 27].

Although we could not replicate the results of Kurtz et al., where fluid challenges resulted in increases of $P_{bt}O_2$ levels, particularly in fluid responders ($>10\%$ CI) [15], we found that $P_{bt}O_2$ rose reactive to fluid boluses administered during episodes of brain tissue hypoxia. Even more important, in 26% of these episodes an increase to normal $P_{bt}O_2$ levels was achieved, indicating a clinically relevant finding, especially as higher $P_{bt}O_2$ levels were associated with improved outcomes in our cohort. This finding is supported by a previous study where the administration of saline boluses resulted in increases of rCBF in areas with low flow at baseline and thus being most vulnerable to ischemia [24]. In the remaining fluid challenges, we could not find an increase in $P_{bt}O_2$ levels and during some episodes $P_{bt}O_2$ even decreased, despite following a goal-directed fluid management with




Table 2 Changes of variables pre-, during, and post-fluid administration in a total of 198 infusions in 48 patients

Variable	Pre infusion	During infusion	Post infusion	p-value**
$P_{bt}O_2$, mmHg	26 ± 10	26 ± 11	26 ± 10	0.885
BTH, percent	49 (25)	50 (25)	41 (21)	0.241
CI, L/min/m ²	3.9 ± 1.1	3.9 ± 1.1	4.0 ± 1.2	< 0.001
SVV, percent	11 ± 6	11 ± 6	9 ± 5	< 0.001
MAP, mmHg	104 ± 15	104 ± 17	106 ± 16	0.116
CPP ^a , mmHg				0.264
IBK	73 ± 9	71 ± 10	74 ± 10	
BRU	109 ± 26	108 ± 28	109 ± 29	
ICP, mmHg	12 ± 8	12 ± 9	12 ± 10	0.582
HR, bpm	86 ± 15	86 ± 15	86 ± 17	0.973
PRx ^b	0.10 ± 0.28	0.08 ± 0.27	0.08 ± 0.30	0.187
Impaired autoregulation (PRx ≥ 0.2) ^b	21 (42)	20 (36)	19 (34)	0.264

$P_{bt}O_2$ brain tissue oxygenation, BTH brain tissue hypoxia, CI continuous cardiac index, SVV stroke volume variation, MAP mean arterial pressure, CPP cerebral perfusion pressure, ICP intracerebral pressure, HR heart rate, PRx pressure reactivity index

^a IBK: zeroed at the level of the Monroe foramen, BRU: zeroed at the heart level

Data are given in mean ± SD or counts (%)

^b Subanalysis in 15 patients

** p-values indicate the difference between pre (1 h before) and post (1 h after) fluid administration

the PiCCO device which allows the prediction of fluid responders. Hemodilution after fluid administration may have outweighed the improvement of the cardiac output in these patients [16]. We could even not demonstrate rising $P_{bt}O_2$ levels in fluid responders as reflected by CI increases. This is an important finding and might indicate that the brain is independent on systemic changes under certain conditions again supporting individualized management with the need of additional monitoring of brain physiologic data. One explanation may lie in the independence of $P_{bt}O_2$ regulation based on the complex interaction between $P_{bt}O_2$ and systemic parameters. $P_{bt}O_2$ has been shown to be a surrogate of CBF [16, 28] although it does not only reflect oxygen delivery but is the net sum of oxygen delivery, consumption, and diffusion [14]. Therefore, factors, such as impaired neurovascular coupling, cerebral edema, fever, spreading depolarizations, neuroinflammation, or lung injury, may have influenced our results [29–33]. Other variables that affect the relation between fluid management and CBF or $P_{bt}O_2$ include the vascular tone and permeability of vessels with third space losses in the presence of leaky capillaries and hypoalbuminemia, a condition commonly observed in critically ill and sedated patients [20, 34]. Also, the state of cerebral autoregulation potentially impacts on $P_{bt}O_2$ responses. Importantly, CBF and $P_{bt}O_2$ are expected to rise in parallel with CPP and CI increases in the presence of impaired autoregulation, while $P_{bt}O_2$ may be independent on CPP/CI changes across intact autoregulation ranges [22]. We found a robust association between cardiac output and brain oxygenation irrespective of the autoregulatory state in a subset of 18 patients. In a considerable number of episodes, the autoregulation was impaired during fluid challenges; however, we could not integrate the autoregulatory state in episodes of BTH at baseline due to restricted patient numbers (5 remaining patients). Impaired autoregulation may explain the missing interaction between CI and CPP when assessing the effect of CI on $P_{bt}O_2$ as one would expect a more pronounced increase in CBF/ $P_{bt}O_2$ secondary to a CI increase when the CPP is low, while patients with an already high cerebral blood supply (with a high CPP) would less benefit from CI increase.

We did not find an association between the volemic status and $P_{bt}O_2$. Neither the absolute fluid input nor a preload dependent status influenced absolute $P_{bt}O_2$ levels. Volume expansion increases cardiac filling pressures with a subsequent increase of the cardiac output according to the Frank-Starling mechanism, which in turn could enhance cerebral blood flow and thereby increased oxygen delivery [35, 36]. Another mechanism theoretically resulting in improved microcirculation in ischemic areas is decreased blood viscosity achieved through volume

administration [37]. However, these effects may be outweighed by complications arising with fluid overload, such as cardiac failure, or pulmonary and cerebral edema [3]. Even more important, hypovolemia as part of the triple-H concept did not result in improved CBF and better functional outcomes in clinical practice [16, 25, 38]. Hemodilution with reduced blood viscosity is associated with decreased hematocrit values which can contribute to reduced oxygen delivery to the brain [39]. In this regard it is important to mention that we aimed at euvolemia in all our patients which was mainly directed by the PiCCO system and clinical examination.

Some limitations to this study merit consideration. Firstly, only patients requiring continuous cardiac and neuromonitoring were included in this study limiting the transferability of our results to good-grade SAH patients. This is also reflected in the high percentage of poor functional outcomes three months after ictus. Secondly, due to the retrospective analysis of prospectively collected data, we do not know the exact indication of fluid challenges, which mainly include fluid maintenance and replacement. To minimize this limitation, we performed a separate analysis for crystalloid and colloid fluids and found that colloids more frequently resulted in CI and MAP increases as expected; however, there was no difference on $P_{bt}O_2$ responses. Thirdly, we cannot conclude whether only fluid challenges or simultaneous effects of other interventions resulted in $P_{bt}O_2$ rises because our institutional protocols foresee interventions without a hierarchical order to treat brain tissue hypoxia. Moreover, we focused on fluids only and did not check for CPP/MAP changes secondary to vasopressor adaptations as this was beyond the scope of the study. However, we give cumulative daily doses of the most important vasopressors used. Fourthly, we did not include other cardiac parameters as derived from echocardiography or blood results as they were not available in all patients included. Fifthly, SVV should only be integrated into clinical decision making if various conditions, including a full mechanical ventilation mode, and the absence of arrhythmias, are fulfilled. Moreover, higher tidal volumes or higher PEEP levels may produce higher variations, and changes in lung or chest compliance or patient position may affect readings. We only included SVV readings during a fully controlled ventilation mode (73%) but were unable to exclude episodes with arrhythmias. Based on our approach of retrospective analysis, we could not adequately define hypovolemia, where low GEDI and high SVV should be associated with a clinical problem, such as hypotension, oliguria, or increased heart rate without another explanation than hypovolemia. Lastly, we may have missed episodes of BTH by cropping the analysis at day 11. However, both $P_{bt}O_2$ and PiCCO monitoring

were performed in the most vulnerable time only and including data points thereafter would have skewed results toward the most severely injured patients.

Conclusions

This study indicates that cardiac performance and brain oxygenation are moderately linked in poor-grade SAH patients. Based on the findings that fluid challenges only resulted in improved $P_{bt}O_2$ levels when brain tissue hypoxia was evident at baseline, there is the need to use both, advanced cardiac and neuromonitoring, in poor-grade SAH patients in order to individualize critical care management.

Abbreviations

SAH: Subarachnoid hemorrhage; PiCCO: Pulse contour cardiac output; CI: Cardiac index; GEDI: Global end-diastolic index; SVV: Stroke volume variation; $P_{bt}O_2$: Brain tissue oxygenation; BTH: Brain tissue hypoxia; CBF: Cerebral blood flow; CT: Computed tomography; ICP: Intracranial pressure; HR: Heart rate; CPP: Cerebral perfusion pressure; MAP: Mean arterial pressure; DCI: Delayed cerebral ischemia; H&H: Hunt&Hess; PRx: Pressure reactivity index.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13613-021-00960-z>.

Additional file 1: Figure S1. Institutional protocol to treat brain tissue hypoxia in IBK. **Figure S2.** Institutional protocol to treat brain tissue hypoxia in BRU. **Table S1.** Baseline characteristics, complications, and outcomes stratified by the two study sites. **Table S2.** Association between CI and $P_{bt}O_2$ (GEE model). **Table S3.** Changes of variables pre, during, and post fluid administration in a total of 198 infusions stratified by brain tissue hypoxia vs. normal brain tissue oxygenation at baseline. **Table S4.** Changes of variables pre, during, and post fluid administration in a total of 198 infusions stratified by CI responders and non-responders. **Table S5.** Changes of variables pre, during, and post fluid administration in a total of 198 infusions stratified by crystalloids vs colloids.

Acknowledgements

The authors would like to thank the nursing staff and the entire team of both intensive care units for their ongoing contribution in the care of our patients.

Authors' contributions

VR and RH designed and oversaw the study. VR, EGB, BAI, LP, MK, AL, AJS, LP, MG, WH, RB, BP, FST, and RH collected the data. VR and BAI performed statistical analysis. VR, FST, and RH wrote the manuscript. All the authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the local ethics committees (Medical University Innsbruck, AN3898 285/4.8, AM4091-292/4.6; Erasme Hospital Brussels, P2019/649). All patients in Innsbruck (IBK) gave informed consent according

to local regulations and it was waived in Brussels (BRU). The conduct of this study conformed to the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

None.

Author details

¹Neurological Intensive Care Unit, Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. ²Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070 Brussels, Belgium. ³Institute of Medical Informatics, UMIT: University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer-Zentrum 1, 6060 Hall, Austria.

Received: 8 August 2021 Accepted: 28 November 2021

Published online: 16 December 2021

References

1. Oddo M, Poole D, Helbok R, Meyfroidt G, Stocchetti N, Bouzat P, et al. Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations. *Intensive Care Med.* 2018;44(4):449–63.
2. Gress DR. Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H. Monitoring of volume status after subarachnoid hemorrhage. *Neurocrit Care.* 2011;15(2):270–274.
3. Rass V, Gaasch M, Kofler M, Schiefficker AJ, Ianosi BA, Steinkohl F, et al. Fluid intake but not fluid balance is associated with poor outcome in nontraumatic subarachnoid hemorrhage patients. *Crit Care Med.* 2019;47:e555.
4. Martini RP, Deem S, Brown M, Souter MJ, Yanez ND, Daniel S, et al. The association between fluid balance and outcomes after subarachnoid hemorrhage. *Neurocrit Care.* 2012;17(2):191–8.
5. Moretti R, Pizzi B. Inferior vena cava distensibility as a predictor of fluid responsiveness in patients with subarachnoid hemorrhage. *Neurocrit Care.* 2010;13(1):3–9.
6. Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. *Chest.* 2020;158(4):1431–45.
7. Chen Z, Venkat P, Seyfried D, Chopp M, Yan T, Chen J. Brain–heart interaction: cardiac complications after stroke. *Circ Res.* 2017;121(4):451–68.
8. Sakka SG, Reuter DA, Perel A. The transpulmonary thermodilution technique. *J Clin Monit Comput.* 2012;26(5):347–53.
9. Tagami T, Kuwamoto K, Watanabe A, Unemoto K, Yokobori S, Matsu-moto G, et al. Optimal range of global end-diastolic volume for fluid management after aneurysmal subarachnoid hemorrhage: a multicenter prospective cohort study. *Crit Care Med.* 2014;42(6):1348–56.
10. Mutoh T, Kazumata K, Ishikawa T, Terasaka S. Performance of bedside transpulmonary thermodilution monitoring for goal-directed hemodynamic management after subarachnoid hemorrhage. *Stroke.* 2009;40(7):2368–74.
11. Mutoh T, Kazumata K, Ajiki M, Ushikoshi S, Terasaka S. Goal-directed fluid management by bedside transpulmonary hemodynamic monitoring after subarachnoid hemorrhage. *Stroke.* 2007;38(12):3218–24.
12. Le Roux P, Menon DK, Citerio G, Vespa P, Bader MK, Brophy GM, et al. Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: a statement for healthcare professionals from the Neurocritical Care Society and the European Society of Intensive Care Medicine. *Neurocrit Care.* 2014;21(Suppl 2):S1–26.
13. Shrestha GS, Suarez JL, Hemphill JC 3rd. Precision medicine in neurocritical care. *JAMA Neurol.* 2018;75(12):1463–4.
14. Rosenthal G, Hemphill JC 3rd, Sorani M, Martin C, Morabito D, Obrist WD, et al. Brain tissue oxygen tension is more indicative of oxygen diffusion than oxygen delivery and metabolism in patients with traumatic brain injury. *Crit Care Med.* 2008;36(6):1917–24.

15. Kurtz P, Helbok R, Ko SB, Claassen J, Schmidt JM, Fernandez L, et al. Fluid responsiveness and brain tissue oxygen augmentation after subarachnoid hemorrhage. *Neurocrit Care*. 2014;20(2):247–54.
16. Muench E, Horn P, Bauhuf C, Roth H, Philipps M, Hermann P, et al. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. *Crit Care Med*. 2007;35(8):1844–51 (**quiz 52**).
17. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2012;43(6):1711–37.
18. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, et al. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. *Cerebrovasc Dis*. 2013;35(2):93–112.
19. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijndicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. *Stroke*. 2010;41(10):2391–5.
20. Vincent JL, Pinsky MR. We should avoid the term “fluid overload.” *Crit Care*. 2018;22(1):214.
21. Kerro A, Woods T, Chang JJ. Neurogenic stunned myocardium in subarachnoid hemorrhage. *J Crit Care*. 2017;38:27–34.
22. Gaasch M, Schiefecker AJ, Kofler M, Beer R, Rass V, Pfausler B, et al. Cerebral autoregulation in the prediction of delayed cerebral ischemia and clinical outcome in poor-grade aneurysmal subarachnoid hemorrhage patients. *Crit Care Med*. 2018;46(5):774–80.
23. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics*. 1986;42(1):121–30.
24. Jost SC, Diringer MN, Zazulia AR, Videen TO, Aiyagari V, Grubb RL, et al. Effect of normal saline bolus on cerebral blood flow in regions with low baseline flow in patients with vasospasm following subarachnoid hemorrhage. *J Neurosurg*. 2005;103(1):25–30.
25. Joseph M, Ziadi S, Nates J, Dannenbaum M, Malkoff M. Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: a study using xenon computed tomographic measurement of cerebral blood flow. *Neurosurgery*. 2003;53(5):1044–51 (**discussion 51–2**).
26. Rass V, Solari D, Ianosi B, Gaasch M, Kofler M, Schiefecker AJ, et al. Protocolized brain oxygen optimization in subarachnoid hemorrhage. *Neurocrit Care*. 2019;31(2):263–72.
27. Chesnut R, Aguilera S, Buki A, Bulger E, Citerio G, Cooper DJ, et al. A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). *Intensive Care Med*. 2020;46(5):919–29.
28. Jaeger M, Soehle M, Schuhmann MU, Winkler D, Meixensberger J. Correlation of continuously monitored regional cerebral blood flow and brain tissue oxygen. *Acta Neurochirurg*. 2005;147(1):51–6 (**discussion 6**).
29. Balbi M, Koide M, Wellman GC, Plesnila N. Inversion of neurovascular coupling after subarachnoid hemorrhage in vivo. *J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab*. 2017;37(11):3625–34.
30. Wang E, Ho CL, Lee KK, Ng I, Ang BT. Effects of temperature changes on cerebral biochemistry in spontaneous intracerebral hematoma. *Acta Neurochir Suppl*. 2008;102:335–8.
31. Schiefecker AJ, Beer R, Pfausler B, Lackner P, Broessner G, Unterberger I, et al. Clusters of cortical spreading depolarizations in a patient with intracerebral hemorrhage: a multimodal neuromonitoring study. *Neurocrit Care*. 2015;22(2):293–8.
32. Stregle RJ, Lang EW, Stark AM, Scheffner H, Fritsch MJ, Barth H, et al. Cerebral edema leading to decompressive craniectomy: an assessment of the preceding clinical and neuromonitoring trends. *Neurol Res*. 2003;25(5):510–5.
33. Robba C, Asgari S, Gupta A, Badenes R, Sekhon M, Bequiri E, et al. Lung injury is a predictor of cerebral hypoxia and mortality in traumatic brain injury. *Front Neurol*. 2020;11:771.
34. van der Jagt M. Fluid management of the neurological patient: a concise review. *Crit Care*. 2016;20(1):126.
35. Wood JH, Fleischer AS. Observations during hypervolemic hemodilution of patients with acute focal cerebral ischemia. *JAMA*. 1982;248(22):2999–3304.
36. Archer DP, Shaw DA, Leblanc RL, Tranmer BI. Haemodynamic considerations in the management of patients with subarachnoid haemorrhage. *Can J Anaesth*. 1991;38(41):454–70.
37. Tranmer BI, Keller TS, Kindt GW, Archer D. Loss of cerebral regulation during cardiac output variations in focal cerebral ischemia. *J Neurosurg*. 1992;77(2):253–9.
38. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. *Stroke*. 2000;31(2):383–91.
39. Tu YK, Heros RC, Karacostas D, Liszczak T, Hyodo A, Candia G, et al. Isovolemic hemodilution in experimental focal cerebral ischemia. Part 2: Effects on regional cerebral blood flow and size of infarction. *J Neurosurg*. 1988;69(1):82–91.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen® journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)